Vascular endothelial growth factor and mTOR pathways in renal cell carcinoma: Differences and synergies of two targeted mechanisms

BJU International

Volumn 104, Issue 11, 2009, Pages 1585-1589

  Mulders, Peter ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Mammalian target of rapamycin; Renal cell carcinoma; Targeted therapy; Vascular endothelial growth factor

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; AXITINIB; BEVACIZUMAB; CEDIRANIB; EVEROLIMUS; FK 506 BINDING PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERFERON; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANOREXIA; ANTINEOPLASTIC ACTIVITY; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RESEARCH; CARDIOTOXICITY; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DEPRESSION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; ENDOTHELIUM CELL; FATIGUE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HAND FOOT SYNDROME; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; INFECTION; KIDNEY CARCINOMA; MUCOSA INFLAMMATION; PATIENT SELECTION; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; SHORT SURVEY; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISCOLORATION; STOMATITIS; THYROID DISEASE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VENOUS THROMBOEMBOLISM; VOMITING; WOUND HEALING IMPAIRMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449389077     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08987.x     Document Type: Short Survey

References (37)

1. Escudier B, Eisen T, Stadler W et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007 356 : 125 134
2. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007 356 : 115 124 (Pubitemid 46089672)
3. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007 356 : 2271 2281 (Pubitemid 46849157)
4. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007 370 : 2103 2111
5. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008 372 : 449 456
6. Brugarolas J. Renal-cell carcinoma - molecular pathways and therapies. N Engl J Med 2007 356 : 185 187
7. Heng DY, Bukowski RM. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets 2008 8 : 676 682
8. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009 27 : 2278 2287
9. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008 13 : 1084 1096
10. Porta C, Szczylik C. Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treat Rev 2009 35 : 297 307
11. Patel PH, Chadalavada RS, Chaganti RS, Motzer RJ. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res 2006 12 : 7215 7220
12. Brenner W, Farber G, Herget T, Lehr HA, Hengstler JG, Thuroff JW. Loss of tumor suppressor protein PTEN during renal carcinogenesis. Int J Cancer 2002 99 : 53 7
13. Velickovic M, Delahunt B, McIver B, Grebe SK. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis. Mod Pathol 2002 15 : 479 485
14. Abraham RT, Gibbons JJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res 2007 13 : 3109 3114
15. Figlin RA. Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC. Nat Clin Pract Oncol 2008 5 : 601 609
16. Pantuck AJ, Seligson DB, Klatte T et al. Prognostic relevance of the mTOR pathway in renal cell carcinoma. Cancer 2007 109 : 2257 2267
17. Land SC, Tee AR. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007 282 : 20534 20543
18. Del Bufalo D, Ciuffreda L, Trisciuoglio D et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006 66 : 5549 5554
19. Lane HA, Wood JM, McSheehy PM et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009 15 : 1612 1622
20. Rini BI, Halabi S, Rosenberg JE et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008 26 : 5422 5428
21. Chu TF, Rupnick MA, Kerkela R et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007 370 : 2011 2019
22. Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A. Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 2008 19 : 1387 1392
23. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007 99 : 81 3
24. Wolter P, Dumez H, Schoffski P. Sunitinib and hypothyroidism. N Engl J Med 2007 356 : 1580 1581
25. Escudier B, Szczylik C, Hutson TE et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 27 : 1280 1289
26. Figlin RA, Hutson TE, Tomczak P et al. Overall survival with sunitinib versus interferon (IFN) -alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). 2008 ASCO Annual Meeting Proceedings. J Clin Oncol 2008 26 (Suppl.): Abstract 5024
27. Dutcher JPSP, McDermott D et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies. Med Oncol 2009 26 : 202 209
28. Logan T, McDermott D, Dutcher J et al. Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features. ASCO Annual Meeting Proceedings 2008. J Clin Oncol 2008 26 (Suppl.): Abstract 8514
29. Schmidinger M, Zielinski CC, Vogl UM et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008 26 : 5204 5212
30. Azad NS, Posadas EM, Kwitkowski VE et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008 26 : 3709 3714
31. Sosman JA, Flaherty KT, Atkins MB et al. Updated results of phase I trial of sorafenib (S) and bevacizumab (B) in patients with metastatic renal cell cancer (mRCC). J Clin Oncol 2008 26 (Suppl.): Abstract 5011
32. Feldman DR, Baum MS, Ginsberg MS et al. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 2009 27 : 1432 1439
33. Patnaik A, Ricart A, Cooper J et al. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J Clin Oncol 2007 25 (Suppl. 18S): Abstract 3512
34. Patel PH, Senico PL, Curiel RE, Motzer RJ. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2009 7 : 24 7
35. Merchan JR, Liu G, Fitch T et al. Phase I/II: trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: phase I safety and activity results. J Clin Oncol 2007 25 Suppl.): Abstract 5034
36. Whorf RC, Hainsworth JD, Spigel DR et al. Phase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC). J Clin Oncol 2008 26 Suppl.): Abstract 5010
37. Schwandt A, Wood L, Bukowski R et al. Temsirolimus in metastatic renal cell carcinoma: safety and efficacy in patients previously treated with VEGF-targeted therapy [abstract 293]. Presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium, Orlando, FL, May 29-June 2, 2009